RXi Pharmaceuticals Announces Phase 1 Study Results for RXI-109

by Benzinga Staff
November 15, 2012 7:05 AM | 30 seconds read | Make a Comment

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

RXi Pharmaceuticals Corporation (OTC: RXII) today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects. This drug candidate is a highly selective CTGF targeting sd-rxRNA® compound that is administered through intradermal injections to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. In this study, 15 volunteers divided over 5 cohorts received single intradermal injections in a dose escalating manner, and blood was drawn at various time points to evaluate the distribution of the drug beyond

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Posted In: NewsGuidance

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.